Summary of Kaul, et al. KarXT EMERGENT-2
Title of the Reference Article: Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial Article DOI: https://doi.org/10.1016/S0140-6736(23)02190-6 Citation: 1. Kaul I, Sawchak S, Correll CU, et al. Group Kaul I, Sawchak S, Correll CU, et…
View On WordPress














